Current status and future directions of multimodality therapy for non-small cell lung cancer of the superior sulcus

Rachel E. Sanborn, Charles Thomas

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Non-small cell lung cancer (NSCLC) tumors originating in the superior sulcus have undergone a significant evolution in terms of both therapy and prognosis over the course of the last 80 years. Initially thought to portend universal mortality, the Pancoast tumor and syndrome, with its characteristic refractory pain and neurologic dysfunction resultant from significant local invasion, was met with a sense of helplessness. The transition from palliative to neoadjuvant radiation, and ultimately to trimodality therapy with neoadjuvant chemoradiation and surgical resection, has dramatically altered the outlook in terms of longevity and quality of life for patients with Pancoast tumors. Combined-modality chemoradiation, followed by surgical resection, has now improved the survival for Pancoast tumors to have a better prognosis than comparatively-staged NSCLC originating in other locations within the lung parenchyma. Problems with local control have largely become supplanted by the most common cause of mortality for NSCLC of all stages: distant failure rates. Ongoing efforts to improve the resectability and to decrease the occurrence of distant metastatic disease will need to be the focus of future clinical trials. The application of improved radiotherapeutic technology, as well as the development of systemically active molecularly targeted agents with lower toxicity profiles than standard cytotoxic chemotherapy, may help guide the next steps in improving the outcomes for superior sulcus tumors.

Original languageEnglish (US)
Pages (from-to)2-9
Number of pages8
JournalCurrent Cancer Therapy Reviews
Volume7
Issue number1
DOIs
StatePublished - 2011

Fingerprint

Pancoast Syndrome
Non-Small Cell Lung Carcinoma
Intractable Pain
Neoadjuvant Therapy
Mortality
Therapeutics
Neurologic Manifestations
Neoplasms
Quality of Life
Clinical Trials
Radiation
Technology
Drug Therapy
Lung
Survival
Direction compound

Keywords

  • Non-small cell lung cancer
  • Pancoast
  • Superior sulcus

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Molecular Medicine

Cite this

Current status and future directions of multimodality therapy for non-small cell lung cancer of the superior sulcus. / Sanborn, Rachel E.; Thomas, Charles.

In: Current Cancer Therapy Reviews, Vol. 7, No. 1, 2011, p. 2-9.

Research output: Contribution to journalArticle

@article{a6f1c157681c4f67b350af80df3631b1,
title = "Current status and future directions of multimodality therapy for non-small cell lung cancer of the superior sulcus",
abstract = "Non-small cell lung cancer (NSCLC) tumors originating in the superior sulcus have undergone a significant evolution in terms of both therapy and prognosis over the course of the last 80 years. Initially thought to portend universal mortality, the Pancoast tumor and syndrome, with its characteristic refractory pain and neurologic dysfunction resultant from significant local invasion, was met with a sense of helplessness. The transition from palliative to neoadjuvant radiation, and ultimately to trimodality therapy with neoadjuvant chemoradiation and surgical resection, has dramatically altered the outlook in terms of longevity and quality of life for patients with Pancoast tumors. Combined-modality chemoradiation, followed by surgical resection, has now improved the survival for Pancoast tumors to have a better prognosis than comparatively-staged NSCLC originating in other locations within the lung parenchyma. Problems with local control have largely become supplanted by the most common cause of mortality for NSCLC of all stages: distant failure rates. Ongoing efforts to improve the resectability and to decrease the occurrence of distant metastatic disease will need to be the focus of future clinical trials. The application of improved radiotherapeutic technology, as well as the development of systemically active molecularly targeted agents with lower toxicity profiles than standard cytotoxic chemotherapy, may help guide the next steps in improving the outcomes for superior sulcus tumors.",
keywords = "Non-small cell lung cancer, Pancoast, Superior sulcus",
author = "Sanborn, {Rachel E.} and Charles Thomas",
year = "2011",
doi = "10.2174/157339411794474164",
language = "English (US)",
volume = "7",
pages = "2--9",
journal = "Current Cancer Therapy Reviews",
issn = "1573-3947",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Current status and future directions of multimodality therapy for non-small cell lung cancer of the superior sulcus

AU - Sanborn, Rachel E.

AU - Thomas, Charles

PY - 2011

Y1 - 2011

N2 - Non-small cell lung cancer (NSCLC) tumors originating in the superior sulcus have undergone a significant evolution in terms of both therapy and prognosis over the course of the last 80 years. Initially thought to portend universal mortality, the Pancoast tumor and syndrome, with its characteristic refractory pain and neurologic dysfunction resultant from significant local invasion, was met with a sense of helplessness. The transition from palliative to neoadjuvant radiation, and ultimately to trimodality therapy with neoadjuvant chemoradiation and surgical resection, has dramatically altered the outlook in terms of longevity and quality of life for patients with Pancoast tumors. Combined-modality chemoradiation, followed by surgical resection, has now improved the survival for Pancoast tumors to have a better prognosis than comparatively-staged NSCLC originating in other locations within the lung parenchyma. Problems with local control have largely become supplanted by the most common cause of mortality for NSCLC of all stages: distant failure rates. Ongoing efforts to improve the resectability and to decrease the occurrence of distant metastatic disease will need to be the focus of future clinical trials. The application of improved radiotherapeutic technology, as well as the development of systemically active molecularly targeted agents with lower toxicity profiles than standard cytotoxic chemotherapy, may help guide the next steps in improving the outcomes for superior sulcus tumors.

AB - Non-small cell lung cancer (NSCLC) tumors originating in the superior sulcus have undergone a significant evolution in terms of both therapy and prognosis over the course of the last 80 years. Initially thought to portend universal mortality, the Pancoast tumor and syndrome, with its characteristic refractory pain and neurologic dysfunction resultant from significant local invasion, was met with a sense of helplessness. The transition from palliative to neoadjuvant radiation, and ultimately to trimodality therapy with neoadjuvant chemoradiation and surgical resection, has dramatically altered the outlook in terms of longevity and quality of life for patients with Pancoast tumors. Combined-modality chemoradiation, followed by surgical resection, has now improved the survival for Pancoast tumors to have a better prognosis than comparatively-staged NSCLC originating in other locations within the lung parenchyma. Problems with local control have largely become supplanted by the most common cause of mortality for NSCLC of all stages: distant failure rates. Ongoing efforts to improve the resectability and to decrease the occurrence of distant metastatic disease will need to be the focus of future clinical trials. The application of improved radiotherapeutic technology, as well as the development of systemically active molecularly targeted agents with lower toxicity profiles than standard cytotoxic chemotherapy, may help guide the next steps in improving the outcomes for superior sulcus tumors.

KW - Non-small cell lung cancer

KW - Pancoast

KW - Superior sulcus

UR - http://www.scopus.com/inward/record.url?scp=79551633735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551633735&partnerID=8YFLogxK

U2 - 10.2174/157339411794474164

DO - 10.2174/157339411794474164

M3 - Article

AN - SCOPUS:79551633735

VL - 7

SP - 2

EP - 9

JO - Current Cancer Therapy Reviews

JF - Current Cancer Therapy Reviews

SN - 1573-3947

IS - 1

ER -